In this study, we show that tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1, which is caused by activated PI3K/AKT pathway. This evidence concerns the gene BARD1 and breast carcinoma.